Index

Abbreviations, diagnostic, 72
Academic medical centers, 120–123
Accountable care organizations, 199
Accreditation, NCQA, 59, 138–139
ACE inhibitors, 115–116
Activated consumer, 212
Acute myocardial infarction, 25, 56, 102–103, 215
Administration
complexity of, 209
costs, 22
and insurance, 41
Administrative data, 215–216
Admission rates, 134
Adverse events, 16
Aetna, 45, 153, 225
Aging, 23
AIDS, 27–28, 34
AIDS and Its Metaphors, 27
Alcohol dependence, 6
Ambulatory surgery, 101
American Academy of Family Physicians, 138
American Academy of Pediatrics, 138
American College of Cardiology, 59–60
American College of Physicians, 47, 138
American Heart Association, 59–60
American Osteopathic Association, 138
Angioplasty, 27, 28
Angiotensin-converting enzyme inhibitors, 28
Antiretroviral therapy (ART), 27–28
Aspirin, 25, 58, 115
Asthma, 93, 117–118
Astra Zeneca, 29, 33
Atenolol, 57
Autonomy, physician, 176–180, 237–239
Avandia, 79
Avastin, 34
Axelrod, Robert, 192
Baby boomers, 23
Back pain, 44–45, 109
Balloon angioplasty, 27
Bar coding, 90, 102, 130
Barium enema, 223
Baseline cost, 20
Behavioral economics, 191–192
Beta-Blocker Heart Attack Trial (BHAT), 56–58, 60
Beta-blockers, 25, 28, 56–60, 103
Black, John, 104–105
Blackford, John, 104
Blood pressure, 63, 66, 137, 157
Bodenheimer, Thomas, 25
Boeing Company, 104
Braunwald, Eugene, 58
Breast cancer, 27, 29
medication costs, 34
reliability of treatment, 6
Bridges to Excellence, 74–76, 156
Brigham and Women’s Hospital, 87, 121, 128, 131
Bristol-Myers-Squibb, 33
Bundled payment methods, 205–207, 232–233
Bypass surgery, 27, 97, 110–113, 171–172
Call centers, 93–94
Cancer, 63
breast, 6, 27, 29, 34
lung, 29
screening, 223
Capitation, 114, 123–124, 146, 164–168, 207–209
and insurance companies, 123, 148, 167–168, 173–174, 199
and nontraditional interventions, 165–166
and pay-for-performance hybrid, 209
and physicians, 166–167
and providers, 166–168, 173–174, 199, 208, 241–242
and quality/efficiency, 148, 233, 241
Care coordinators, 67, 140–141
Career choices, medical, 12
Care Management Institute, 114, 117
Casalino, Lawrence, 94
Case rate payment model, 146, 205–207
Geisinger CABG program, 112–113, 171–172
and quality/efficiency, 232–233
Case studies
genetic markers, 29–33
multi-problem patients, 3–5, 211–212, 234
physician autonomy, 177–178
Catastrophic protection, 43
Cedars Sinai Hospital, 86
Chemotherapy, 107–108
Choice, patient, 166, 169
and capitation, 241–242
and narrowed network approach, 148–149
and quality, 234–235
Cholecystectomy, 198
Cholesterol, 103, 117
high-density lipoprotein, 33
testing, 171
Chronic disease, 63, 66–67
chronic care model, 91–93
disease management, 153
and EMRs, 82–83
and patient cost exposure, 224–225
Cleveland Clinic, 98
Clinical data, 215–216
Clinical information systems, 93
Clinical integration, 246
Clinic model, 119, 240
Clinton, Bill, 99
Clopidogrel, 25
Closed systems, 119
Colonoscopy, 223
Common terminology, 72
Commonwealth Fund Commission report, 7, 61–62, 137–138
Commonwealth Fund Survey of 2008, 18
Communication
among physicians, 35
among providers, 65
and EMRs, 72–73
and multiple sites, 48
and patients, 49, 63–65, 110
with specialists, 48
Community resources, 92
Competition, 246
Complex medical conditions, 3–5, 63, 67–68, 117, 153, 211–212
Complication rates, 112–113, 235
Computerized physician order entry (CPOE), 130
costs, 87, 188
and hospitals, 75, 86–88, 128
Confidentiality, 49–50
Conflict resolution, 191
Congestive heart failure, 93–94, 134
Consumer price inflation, 241
Consumers, patients as, 212, 227, 236
Continuous care, 67
Coordinated care, 67, 140–141, 211–212
Copayments, 149, 209, 236–237
Coronary artery bypass graft (CABG), 97, 110–113
and case rates, 171–172, 206
mortality rates, 181, 217
Coronary artery disease, 6, 116–117
Costs, 20–26. See also Efficiency
and aging population, 23–24
case rate approach, 112–113
chronic care, 93, 224–225
CPOE, 87, 188
disease management, 94, 153–154
doctors’ and nurses’ salaries, 12, 24, 189, 241
drug development, 33–34
electronic medication administration, 90, 188
and EMRs, 83–85, 188
expenditure patterns, 21–22
hospitals, 188–189
immunization, 34
increases in, 20–21, 164
indirect, 34
information systems, 188
insurance premiums, 198, 200–201
and market forces, 236–237
and organized care, 65
patient awareness of, 43–44, 218–220, 223–224, 231, 236
personnel, 189
public reporting on, 218–219, 231
and quality of care, 26, 235–236
technology and physical plant, 24–25
Cost shifting, 189, 201, 209–210, 220–221, 225–226
Crossing the Quality Chasm, 5, 61–63
CT scan, 26–27, 45, 184–185
Data analysis, 144, 149–152. See also
Public reporting
de Brantes, Françoise, 73
Decision support, 92. See also Information systems
and efficiency, 65, 135, 171
and error reduction, 71–72, 130–131
Deductibles, 149, 209
Defensive medicine, 23
Delivery organizations. See also Partners
HealthCare System; Providers; Tightly structured organizations
Geisinger Health System, 84, 97–98, 109–113, 140, 171–172, 206
integrated, 99–100, 114, 119–120
Kaiser Permanente, 84, 98, 113–117, 148, 168
Veterans Health Administration (VHA), 89, 100–103, 131, 168
Virginia Mason Medical Center, 44–45, 98, 103–109, 192
Demographic trends
and pace of change, 176
and rising health costs, 23
Depression, 63, 94, 157
Diabetes, 63
and cholesterol testing, 171
and chronic care programs, 93
insulin therapy, 6, 28
and physician report cards, 180–181
population-based care, 82–83, 113, 115–116, 132–133
recent medication for, 28
reliability of care, 132
and team practice, 66–67
Diagnosis-related group (DRG) system, 205–206
Discharge guidelines, 48, 116
medication, 87, 131–132
and PCP visits, 140
and public reporting, 243
Disease management, 44, 93–95, 133–135. See also Population-based care
costs, 94, 153–154
defined, 152
diabetes, 82–83, 113, 115–116, 132–133
and fee-for-service payment, 134
and health plans, 94, 152–154
heart disease, 94, 116–117, 134
and information systems, 95
and performance incentives, 171
and subcapitation, 172
Doctor-patient relationship, 16–18
“Dose of Competition, A,” 201
Drugs. See Medication
Dual-earner couples, 13–14

Eastern Kansas Veterans Affairs Medical Center, 102
“Economic and Budget Issue Brief,” 219
Education. See also Patient education
and families, 13–14
physician, 10, 12
and reliability of health care, 7
Efficiency, 65, 106–107. See also Costs
and capitation, 148, 233, 241
development, 65, 135, 171
and EMRs, 171
and fee-for-service payment, 195, 232
and negotiation, 191, 201
and payment methodologies, 170, 173, 232–233
and performance incentives, 147, 171, 232
and provider motivation, 220
and public reporting, 231
and testing costs, 135–136, 171, 185
and tiered networks, 149
and variation data, 183, 186
Elderly, health costs of, 23–24
Electronic medical records (EMRs), 63, 71–72, 75, 76–86, 139
and chronic disease, 82–83
costs of, 83–85, 188
diversity of, 11
and drug information, 79–82
and efficiency, 171
and error detection, 141–142
extent of use, 49, 76–77
FDA guidelines, 79
Electronic medical records (EMRs) (cont.)
functions of, 76, 78, 84–85
in Partners HealthCare, 128–130
patient access to, 85, 159
and provider organization, 84
and public reporting, 243
and safety, 66–67, 131–132
and time management, 85
Vista, 101–102
Electronic medication administration,
88–90, 188
Electronic prescribing, 129–130, 171, 243
Email, 211
Emergency room visits, 223
Emphysema, 58
Employers, 154–158
and health plans, 155–158
and negotiation with providers, 198
and payment models, 195–196
and preventive care, 43, 154
and provider organization, 244–245
value-based purchasing, 155–156
workplace-based interventions,
156–157
Enfuvirtide, 28
Epidermal growth factor receptor
(EGFR), 30–31
Episodes of care, 206
Error reduction, 72, 86–87. See also Safety
disease management, 152
and EMRs, 141–142
and medication administration, 89, 128,
130–131
and physicians’ reputations, 180
Evidence-based medicine, 50
“Evidence on the Costs and Benefits of
Health Information Technology,” 84
Families, 13–14
Fecal occult blood testing, 223
Federal Trade Commission, 246
Fee-for-service payment, 63, 140, 146
cap on increasing, 240–241
and chronic care programs, 93
and disease management, 134
and efficiency, 195, 232
and medical home model, 202
and nonphysician personnel, 139
and patients’ health, 145
and provider organization, 147, 173,
195–196
Flexible payment approach, 241, 244
Flu shots, 109
Fragmentation, health care, 37–51
EMRs, 49
and insurance companies, 38
and patient choice, 234
and patient-doctor relations, 39–40
and payment, 40–45
and practice patterns, 40
and providers, 45–50
Galvin, Robert S., 73
Game theory, 192
Gefitinib, 29
Geisinger Health System, 84, 97–98,
109–113, 140, 171–172, 206
General Electric (GE), 73–74
Generic drugs, 224, 236
Genetic markers, 28–29, 32–33
Global capitation, 114
Government policy, 246–247
Government underpayment, 209–210
Grand Rounds, 10
Group Health Cooperative of Puget
Sound, 92, 98
Group practice, 55, 175–176. See also
Team practice
Group purchasing, 43
Guaranteed care, 112
Haber, Daniel A., 30–32
Hand washing, 187
Harrison’s Principles of Internal Medicine,
10
Health and Human Services, 213
Health Care Financing Administration, 59
Health care system, U.S. See also
Fragmentation, health care
Commonwealth Fund Commission
report, 7, 61–62, 137–138
Commonwealth Fund Survey of 2008,
18
increased utilization of, 24
Institute of Medicine reports on, 5
and other countries, 7, 20–21
overuse and misuse in, 8
RAND report of 2003, 6–7
reliability studies of, 5–7
Health insurance plans, 144–145. See also
Insurance product design
and capitation, 123, 148, 167–168,
173–174, 199
and chronic care, 92
and data analysis, 144, 149–152
and disease management, 94, 152–154
and disease specialization, 38, 44
and drug coverage, 81–82
and employers, 155–158
extent of coverage, 43
financial resources of, 144
HDHPs, 221–228
and hospitals, 196–197, 200
managed care, 120–121, 123
and Medicaid/Medicare patients, 192
and member turnover, 43
and mental health, 44
motivation of, 144
narrowed/tiered network products, 148–149, 156
and national system, 41
and patient choice, 148–149
and payment models, 195–196
and performance incentives, 147, 170, 200
and physician autonomy, 238–239
and provider organization, 189–190, 196–197, 199–202, 244–245
and small providers, 196
and testing, 45
Health risk assessment questionnaires, 156–157
Health savings accounts (HSAs), 221–223, 226
Health Vault, 160
Heart attack, 63
acute myocardial infarction, 25, 56, 102–103, 215
and aspirin, 58
and beta-blockers, 25, 28, 56–60, 103
coronary artery bypass graft (CABG), 27, 97, 110–113, 171–172, 181, 206
and public reporting, 216–217, 243
VHA study, 102–103
and workplace stress, 157–158
Heart disease
and chronic care programs, 93
and chronic care disease, 6, 116–117
and disease management, 94, 116–117, 134
Heart Disease, 58
Heart valve replacement, 28
HEDIS measures, 213
Heparin, 89
Hepatitis B, 15
High-deductible health insurance plans (HDHPs), 221–228
High Performance Medicine program, 125–137
High-risk patients, 93–95
HIV, 27–28, 34
HMOs. See also Health insurance plans
beta-blockers as performance measure, 56, 59
and negotiation with providers, 198
and quality measures, 213
Hodgkin’s disease, 185–186
Hospitals
admission rates, 134
and case rate model, 233
costs, 188–189
and CPOE, 75, 86–88, 128
defered maintenance, 189
discharge guidelines, 48, 87, 116, 131–132, 140, 243
and DRGs, 205–206
inpatient problems, 87–88
and insurance companies, 196–197, 200
Leapfrog quality measures, 75–76
and managed care plans, 120–121
and mortality rates, 216
and payment incentives, 59
quality measurement and reporting, 59, 213, 215, 217
reduction of hospitalizations, 65, 199, 206, 235
relations with PCPs, 48
and safe medication administration, 88–90
teaching, 34
“Humanware,” 63, 71, 75
Hypertension, 63, 66, 137, 157
Identification bracelet, 90, 130
Illness as Metaphor, 27
Immunizations, 6, 34
Incentives, 173, 191–192. See also Performance
and efficiency, 147, 171, 232
and flexible payment, 241
and health plans, 147, 170, 200
and hospitals, 59
medical home model, 232
pay-for-performance programs, 150–151, 170–171, 204, 232
<table>
<thead>
<tr>
<th>Term</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Independent practice associations (IPAs), 123–124</td>
<td>272</td>
</tr>
<tr>
<td>Independent practice organizations (IPOs), 123</td>
<td>272</td>
</tr>
<tr>
<td>Indirect costs, 34</td>
<td>272</td>
</tr>
<tr>
<td>Individual mandate approach, 226</td>
<td>272</td>
</tr>
<tr>
<td>Inflation, 241</td>
<td>272</td>
</tr>
<tr>
<td>Influenza vaccination, 109</td>
<td>272</td>
</tr>
<tr>
<td>Information overload, 71</td>
<td>272</td>
</tr>
</tbody>
</table>
Massachusetts General Hospital, 121, 131
Mayo Clinic, 98
McGlynn, Elizabeth, 6, 35
Media, health information in, 16
Medicaid, 135, 189, 192, 209, 237, 242
Medical home model, 172, 202, 207
incentives of, 232
and primary care physicians, 120, 137–141
Medical inflation, 241
Medical knowledge, explosion of, 10–11
Medical/Psychiatric High Risk Case Management Program, 153–154
Medicare, 197, 237, 242
and heart attack treatment, 59
and hospitalizations, 205–206
and mammography, 103
patient-physician interactions, 39
and providers’ costs, 189, 192
spending per beneficiary, 40
underpayment by, 209–210
Medicare Advantage, 208
Medication
bar coding, 90
cost-effective, 44
and CPOE, 75, 86–88, 128
development costs, 33–34
diabetes, 28
effectiveness review of, 247
electronic administration of, 88–90, 188
and EMR information, 79–82
generic, 224, 236
heart disease, 25, 28
innovative, 27
insurance coverage of, 81–82
and safety, 88–90, 101–102, 130–132, 193
smart drugs, 29–32
MEDLINE, 10
Mental health, 44
Metformin, 28
Methodist Hospital, 89
Metoprolol, 57
Microsoft, 160
MRI, 26–27, 45, 198
MULTIFIT, 116–117
Mycobacterium avium complex disease, 27
Myocardial infarction, 25, 56, 102–103, 215
Nadolol, 57
Nakao, Chihiro, 107
Narrowed network insurance, 148–149
National Ambulatory Medical Care Survey, 46–47
National Committee for Quality Assurance (NCQA), 56, 74–75, 159
accreditation, 59, 138–139
HEDIS measures, 213
National Institute for Health and Clinical Excellence, 247
National Institutes of Health, 56–57
National Quality Forum, 159
Negotiation, 191, 198, 201
Networks of physicians, 55
“Never events,” 235–236
New England Journal of Medicine, 10
Nexium, 80–81
Nonnucleoside reverse transcriptase inhibitors, 28
Nonphysician personnel, 92, 139–141, 207, 238
Nurses
as care coordinators, 67, 140–141
and disease management, 94, 134, 152–153
and medication administration, 90
and population-based care, 116–117
salaries of, 24, 189, 241
shortage of, 198
telephonic coaching, 135
Obama administration, 246–247
Office visits, 17, 47–48, 84, 140
Omeprazole, 81
Organized care, 63–65, 229
Parsons, Talcott, 220
Partners HealthCare System, 43, 78, 84, 120–137, 157, 170
and capitation, 165, 167
corporate organization of, 122
Heart Failure Program, 134
High Performance Medicine, 125–137
information systems in, 126–132, 171
medication administration in, 130–132
Partners Community HealthCare, Inc. (PCHI), 123–124
and pay-for-performance contracts, 124–125, 131, 137, 141, 147, 171
Signature Initiatives, 125
<table>
<thead>
<tr>
<th>Index</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Partners HealthCare System (cont.)</td>
<td>193</td>
</tr>
<tr>
<td>and systems theory</td>
<td>193</td>
</tr>
<tr>
<td>testing efficiency</td>
<td>135–137</td>
</tr>
<tr>
<td>and variation data</td>
<td>185–186</td>
</tr>
<tr>
<td>Pasteur, Louis</td>
<td>32</td>
</tr>
<tr>
<td>Patient education</td>
<td>66, 92</td>
</tr>
<tr>
<td>and chronic disease</td>
<td>66, 92</td>
</tr>
<tr>
<td>and complex conditions</td>
<td>67</td>
</tr>
<tr>
<td>and disease management</td>
<td>94–95, 117</td>
</tr>
<tr>
<td>Internet portals</td>
<td>159</td>
</tr>
<tr>
<td>personal health records</td>
<td>159–160</td>
</tr>
<tr>
<td>Patient identification bracelet</td>
<td>90, 130</td>
</tr>
<tr>
<td>Patients</td>
<td>212, 227, 236</td>
</tr>
<tr>
<td>as activated consumers</td>
<td>212, 227, 236</td>
</tr>
<tr>
<td>and choice</td>
<td>148–149, 166, 169, 234–235, 241–242</td>
</tr>
<tr>
<td>with chronic disease</td>
<td>63, 66–67, 92</td>
</tr>
<tr>
<td>and communication</td>
<td>49, 63–65</td>
</tr>
<tr>
<td>with complex medical conditions</td>
<td>63, 67–68</td>
</tr>
<tr>
<td>and consumer organizations</td>
<td>158–159</td>
</tr>
<tr>
<td>and cost awareness</td>
<td>43–44, 218–220, 223–227, 231, 236</td>
</tr>
<tr>
<td>and disease management programs</td>
<td>152–153</td>
</tr>
<tr>
<td>doctor-patient relationship</td>
<td>16–18</td>
</tr>
<tr>
<td>and EMRs</td>
<td>85, 159</td>
</tr>
<tr>
<td>expanded treatment population</td>
<td>26</td>
</tr>
<tr>
<td>expectations and experience of</td>
<td>18, 35, 159</td>
</tr>
<tr>
<td>frequency of physician visits</td>
<td>17</td>
</tr>
<tr>
<td>high-risk</td>
<td>93–95</td>
</tr>
<tr>
<td>and information systems</td>
<td>110</td>
</tr>
<tr>
<td>and medical home</td>
<td>137</td>
</tr>
<tr>
<td>and organized care</td>
<td>65, 245</td>
</tr>
<tr>
<td>participation of</td>
<td>35, 73</td>
</tr>
<tr>
<td>and performance data</td>
<td>151</td>
</tr>
<tr>
<td>and public reporting</td>
<td>214, 218–219</td>
</tr>
<tr>
<td>relations with physicians</td>
<td>16–18, 39–40</td>
</tr>
<tr>
<td>and systemic change</td>
<td>164</td>
</tr>
<tr>
<td>uninsured</td>
<td>135</td>
</tr>
<tr>
<td>worried/unworried well</td>
<td>63, 68–69</td>
</tr>
<tr>
<td>Patient safety</td>
<td>5</td>
</tr>
<tr>
<td>Institute of Medicine reports on</td>
<td>5</td>
</tr>
<tr>
<td>and medication administration</td>
<td>88–90</td>
</tr>
<tr>
<td>physicians’ report on</td>
<td>8</td>
</tr>
<tr>
<td>Patterns of practice</td>
<td>40, 185</td>
</tr>
<tr>
<td>Pay-for-performance programs</td>
<td>124–125, 131, 137, 141, 202–205</td>
</tr>
<tr>
<td>and capitation</td>
<td>209</td>
</tr>
<tr>
<td>and incentives</td>
<td>150–151, 170–171, 204, 232</td>
</tr>
<tr>
<td>limitations of</td>
<td>203</td>
</tr>
<tr>
<td>and patient populations</td>
<td>204–205</td>
</tr>
<tr>
<td>and provider organization</td>
<td>146–147, 203</td>
</tr>
<tr>
<td>and quality/efficiency</td>
<td>231–232</td>
</tr>
<tr>
<td>and small providers</td>
<td>204</td>
</tr>
<tr>
<td>Payment</td>
<td>40–45, 164–174, 195–210. See also Capitation; Fee-for-service payment</td>
</tr>
<tr>
<td>bundled payment</td>
<td>205–207, 232–233</td>
</tr>
<tr>
<td>and compensated activities</td>
<td>42</td>
</tr>
<tr>
<td>copayment and deductibles</td>
<td>149</td>
</tr>
<tr>
<td>and efficiency</td>
<td>170, 173, 232–233</td>
</tr>
<tr>
<td>and employers</td>
<td>195–196</td>
</tr>
<tr>
<td>flexible payment approach</td>
<td>241, 244</td>
</tr>
<tr>
<td>group purchasing</td>
<td>43</td>
</tr>
<tr>
<td>and health plans</td>
<td>195–196</td>
</tr>
<tr>
<td>medical home model</td>
<td>120, 137–141, 172, 202, 207, 232</td>
</tr>
<tr>
<td>models of</td>
<td>145–147</td>
</tr>
<tr>
<td>in narrowed/tiered networks</td>
<td>148–149</td>
</tr>
<tr>
<td>and negotiation</td>
<td>44</td>
</tr>
<tr>
<td>and organizational evolution</td>
<td>169–170</td>
</tr>
<tr>
<td>patient awareness of</td>
<td>43–44</td>
</tr>
<tr>
<td>payment dysfunction</td>
<td>209–210</td>
</tr>
<tr>
<td>problems of</td>
<td>168–169</td>
</tr>
<tr>
<td>single-payer system</td>
<td>209, 237</td>
</tr>
<tr>
<td>and small providers</td>
<td>170, 204</td>
</tr>
<tr>
<td>subcapitation</td>
<td>146, 148, 172–174</td>
</tr>
<tr>
<td>and technological progress</td>
<td>148</td>
</tr>
<tr>
<td>and testing</td>
<td>45</td>
</tr>
<tr>
<td>Penn State University</td>
<td>109</td>
</tr>
<tr>
<td>Performance. See also Public reporting improvement</td>
<td>60</td>
</tr>
<tr>
<td>incentives</td>
<td>147, 150–151, 170–171, 173, 191–192, 200</td>
</tr>
<tr>
<td>measurement</td>
<td>56, 59, 179–182, 243–244</td>
</tr>
<tr>
<td>and variation data</td>
<td>183–187</td>
</tr>
<tr>
<td>Perlin, Jonathan</td>
<td>102</td>
</tr>
<tr>
<td>Personal health records</td>
<td>159–160</td>
</tr>
<tr>
<td>Personalized care</td>
<td>67</td>
</tr>
<tr>
<td>Personnel costs</td>
<td>189</td>
</tr>
<tr>
<td>PET scan</td>
<td>26–27, 186</td>
</tr>
<tr>
<td>Pfizer</td>
<td>33</td>
</tr>
<tr>
<td>Pharmaceutical industry</td>
<td>22</td>
</tr>
</tbody>
</table>
Index

Pharmacy, tiered, 236–237
Pharmacy benefit management, 44
Physical therapy, 45
Physician-hospital organizations (PHO), 123–124, 200
Physician Office Link program, 138–139
Physicians. See also Primary care physicians (PCPs)
accountability to colleagues, 187
accreditation of, 138–139
as all-knowing healers, 9–10, 50–51
autonomy of, 176–180, 237–239
Bridges to Excellence standards, 74–76
and capitation, 166–167
and case rate model, 233
computerized support for, 65
continuing education of, 10
daily routines of, 8–9
decision support for, 65, 71–72
and disease management programs, 152–153
doctor-patient relationship, 16–18
and DRGs, 205–206
duration of patient visits, 17
and EMR adoption, 129
and evidence-based medicine, 50
and extra testing, 23
and group practice, 55
and lifestyle, 12–13
and managed care plans, 123
and mortality rates, 217
and performance incentives, 147, 170, 173, 200
and performance measurement, 179–182, 244
and proactive care, 91
and public reporting, 213, 215, 244
relations with patients, 16–18
report cards, 51
salaries of, 12, 24
and team practice, 46–47
and technological progress, 35, 39
and testing data, 135–136
tunnel vision of, 177
and variation data, 183–187
workload of, 72
Pneumocystis jiroceci pneumonia, 27
Pneumonia, 215
Policy, government, 246–247
Policymakers, 246–247
Population-based care, 23, 67–69. See also
Disease management
ALL program, 115–116
asthma, 117–118
chronic care model, 91–93
complex medical conditions, 117
coronary artery disease, 116–117
and CPOE, 87
diabetes, 82–83, 113, 115–116, 132–133
disease management, 44, 93–95, 133–135, 152–154
and EMRs, 82–83
in Partners HealthCare, 132–133
and performance incentives, 147
and physician report cards, 181
and preventive programs, 235
and provider organization, 199
Portals, patient, 159
Prescription drugs
and HDHPs, 224–225
increase in use of, 16
Prescriptions
electronic, 129–130, 171, 243
variation in, 183
Preventive care, 43, 154, 235. See also
Interventions; Quality
Price transparency, 218–219
Prilosec, 81
Primary care physicians (PCPs), 12
characteristics of care, 138
and discharge summaries, 48
and EMRs, 77
and hospitals, 48
and information management, 14–17
and lifestyle, 12
and medical home model, 120, 137–141, 232
and missing data, 15
and patient load, 15, 39–40
and specialists, 47–48
and VHA, 100
and worried well, 68
Privacy, 160
Proactive care, 66, 68, 91
Proceduralist, 47–48
Process improvement, 192–193
Progress. See Technological progress
Prometheus Payment, Inc., 206
Propranolol, 56–57
Prospective payment, 164–165, 171–174, 235, 248
Prospect theory, 191–192, 204
Protease inhibitors, 28
ProvenCare, 111
Index

“Six Sigma Design Team,” 73–74
“Skin in the game,” 219–220
Small practices, 119–120, 140–141, 195, 245
and information systems, 188
and insurance companies, 196
and pay-for-performance, 204
and payment methodologies, 170
and performance incentives, 147, 170
Smart drugs, 29–32
Smart pumps, 130–131
Smoking cessation, 103, 235
Social network analysis, 193
Sontag, Susan, 27
Specialization, 11
and lifestyle, 12–13
physician visits, 47–48
and primary care, 12
proceduralist, 47–48
and technological progress, 35
Statins, 25, 28, 117–118, 198
Statistical techniques, 181–182
Steele, Glenn, 110
Stents, 27
Stop-loss insurance, 208
Strategic planning, 190
Streamlining treatment, 107–108
Subcapitation, 146, 148, 172–174
Sulfonylureas, 28
Surgery
minimally invasive, 28
reducing complications in, 102
surgical specialties, 12
Sweden, 27
Systems theory, 193

Tax shelter, 222–223
Teaching hospitals, 34
Team practice, 46–47, 51, 71–72
and accountability, 187
and case rates, 172
and chronic disease, 66
and complex medical conditions, 67
and medical home model, 207
and physician autonomy, 178–180, 238
and physician compact, 104
Technological Change and the Growth of Health Care Spending, 20–21
Technological progress, 19–36
case study, 29–33
challenges of, 34–36
costs of, 20–26
effectiveness review of, 247
and health care delivery, 38
heart disease, 28
HIV infections, 27–28
medication, 27, 29–32
and payment, 148
and systemic change, 58–59, 163–164
Terminology, common, 72
Testing
cost-effectiveness of, 135–136, 171, 185
and HDHPs, 223
and payment, 45
and performance incentives, 171
variation data, 40, 183–186
Tiered network insurance, 149, 156, 226–227
Tiered pharmacy formularies, 236–237
Tightly structured organizations,
147–148. See also Delivery organizations; Providers
and capitation, 208
extent of, 195
integrated delivery organization, 114, 119
integrated service network (ISN), 99–100
and patient data, 150
and payment, 165, 168–169, 173
Tit-for-tat approach, 192
To Err Is Human, 5
Torcetrapib, 33
Toyoda, Sakichi, 105
Toyota Production System, 104, 106, 193
Toyota Way, 105–106
Trust, 16–18
Tuberculosis, 27
Tumor markers, mutations of, 31
“Tyranny of the Urgent,” 92
Underpayment, government, 209–210
Uninsured patients, 135
Universal patient identification number (UPIN), 49
Unworried well, 63, 68–69
Urinary tract infection, 14
Vaccination, influenza, 109
Value-based purchasing, 155–156, 225–226
Variation data, 40, 183–187, 193, 238
Veterans Health Administration (VHA), 89, 97–103, 131
and capitation, 168
improvements in service, 100–102
quality of care, 102–103
Vista, 101–102
Veterans Integrated Service Network (VISN), 99–100
Virginia Mason Medical Center, 44–45, 98, 103–109, 192
Visits
emergency room, 223
office, 17, 47–48, 84, 140
Vista (Veterans Health Information System and Technology Architecture), 101–102

Wagner, Edward H., 92
WebMD, 156–157
Weight loss surgery, 28
Worried well, 63, 68